9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene | 1280663-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene
• 英文别名: 10-methyl-2,3,5,6,7,11c-hexahydro-1H-pyrido[3',2':4,5]pyrrolo[2,3-g]indolizine；14-methyl-6,10,12-triazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),11(16),12,14-tetraene
• CAS: 1280663-40-2
• 化学式: C₁₄H₁₇N₃
• 分子量: 227.309
• InChiKey: IKQNICMCGVCWLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-乙烯基吡啶 、 9-methyl-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene 在 四丁基氟化铵 、 sodium hydroxide 作用下， 反应 18.0h， 以58 mg的产率得到9-methyl-6-(2-pyridin-3-yl-ethyl)-2,3,4,5,6,10c-hexahydro-1H-3a,6,7-triaza-cyclopenta[c]fluorene
  参考文献：
  名称：

  COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION

  摘要：

  氢化吡啶并[4,3-b]吲哚，吡啶[3,4-b]吲哚和氮杂七元[4,5-b]吲哚被描述。这些化合物可能与肾上腺素受体α2B结合并拮抗。这些化合物也可能与肾上腺素受体α1B结合并拮抗。这些化合物可能在治疗中发挥作用，例如（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收。这些化合物也可用于治疗对降低血压有反应或预期会有反应的疾病或症状。特别描述了使用这些化合物治疗心血管和肾脏疾病。

  公开号：

  US20150266884A1

文献信息

• [EN] COMPOUNDS AND METHODS OF TREATING DIABETES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DU DIABÈTE
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2014031165A1

  公开（公告）日：2014-02-27

  Hydrogenated pyrido[4,3-b]indoles and pyrido [3, 4-b] indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2β; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  描述了氢化吡啶并[4,3-b]吲哚和吡啶[3,4-b]吲哚。这些化合物可能与肾上腺素能受体a2A结合并起拮抗作用。这些化合物也可能与肾上腺素能受体α2β结合并起拮抗作用；或者这些化合物不是肾上腺素能受体α2β的拮抗剂，这些化合物与第二药物一起使用，该第二药物降低或预期降低个体的血压。这些化合物可能在疗法中发挥作用，例如，调节血糖水平，增加胰岛素分泌，并治疗疾病或病况，这些疾病或病况对增加胰岛素产生有反应或预期有反应。特别描述了使用这些化合物治疗2型糖尿病。
• [EN] PYRIDO[4,3-B]INDOLES AND METHODS OF USE<br/>[FR] PYRIDO[4,3-B]INDOLES ET LEURS MÉTHODES D'UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2011038161A1

  公开（公告）日：2011-03-31

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体中的组胺受体。其中描述了吡啶并[4,3-b]吲哚，以及包含这些化合物的药物组合物和使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。
• PYRIDO[4,3-B]INDOLES AND METHODS OF USE
  申请人：Jain Rajendra Parasmal

  公开号：US20110245272A1

  公开（公告）日：2011-10-06

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体的组胺受体。其中描述了吡啶并[4,3-b]吲哚，以及包含这些化合物的制药组合物和使用这些化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• COMPOUNDS AND METHODS OF TREATING DIABETES
  申请人：Protter Andrew Asher

  公开号：US20130053367A1

  公开（公告）日：2013-02-28

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α 2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  本文描述了氢化吡啶并[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素受体α2A。这些化合物也可以结合并拮抗肾上腺素受体α2B；或这些化合物不是肾上腺素受体α2B的拮抗剂，并且这些化合物与第二个降低或预计降低个体血压的药物一起使用。这些化合物可以用于治疗，例如，调节血糖水平、增加胰岛素分泌和治疗对增加胰岛素产生有反应或预计会有反应的疾病或病况。特别描述了使用这些化合物治疗2型糖尿病的用途。
• Pyrido[4,3-B]indoles and methods of use
  申请人：Medivation Technologies, Inc.

  公开号：US09045482B2

  公开（公告）日：2015-06-02

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体中的组胺受体。其中描述了吡啶并[4,3-b]吲哚，以及包含这些化合物的药物组合物和使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍，精神疾病，神经递质介导的疾病和/或神经元疾病。